Sunesis Pharmaceuticals Inc. (SNSS)
Symbol Info
Listed Symbol SNSS
Name Sunesis Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $237,000
Latest Fiscal EPS $-0.75
Price Info
21 Day Moving Average $0.7617
21 Day EMA $0.738430
50 Day Moving Average $0.8138
50 Day EMA $0.794480
200 Day EMA $1.002210
200 Day Moving Average 0.844140
52 Week High $1.99
52 Week Low $0.20
52 Week Change $-66.560200
Alpha -0.028628
Beta 2.9318
Standard Deviation 0.281213
R2 0.128320
Periods 60
Share Information
10 Day Average Volume 264,631
20 Day Average Volume 311,343
30 Day Average Volume 453,778
50 Day Average Volume 380,119
Outstanding Shares 111,320,000
Float Shares 109,326,004
Percent Float 98.21%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 79
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 10,060,855
Institute Holdings Percent 27.200000
Institute Sold Previous 3 Months 996,740
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 9
Insider Holdings Percent 1.80%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,993,996
Price Change
7 Day Price Change $-0.0393
7 Day Percent Change -5.80%
21 Day Price Change $-0.2331
21 Day Percent Change -26.74%
30 Day Price Change $-0.3504
30 Day Percent Change -35.43%
Month To Date Price Change $-0.0812
Month To Date Percent -11.28%
90 Day Price Change $-0.1713
90 Day Percent Change -21.15%
Quarter To Date $-0.0812
Quarter To Date Percent -11.28%
180 Day Price Change $-0.9013
180 Day Percent Change -58.53%
200 Day Price Change $-0.6413
200 Day Percent Change -50.10%
Year To Date $0.223000
Year To Date Percent 53.64%
Profile
Description Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.
Details
Issue Type CS
Market Cap $71,100,084
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 111,320,000
CEO Dayton Misfeldt
Employees 29
Last Audit UE
Classification
CIK 0001061027
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 395 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
Website http://www.sunesis.com
Facisimile +1 650 266-3501
Telephone +1 650 266-3500
Email
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -3,995.5
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $81,615,268
Price To Sales -
Price To Free Cash -3.9
PE High Last 5 Years -
Price To Book 16.6
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 16.6
Financial Strength
Total Debt To Equity 1.4
Int Coverage -24.7
Current Ratio 2.3
Leverage Ratio -4.6
Quick Ratio 1.4
Long Term Debt To Capital 0.04
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -114.26
Return On Equity 773.07
Return On Capital -
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
SNSS
Sunesis Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.